110 related articles for article (PubMed ID: 38852052)
1. "WATCH AND WAIT" STRATEGY IN RECTAL CANCER PATIENTS WITH A COMPLETE CLINICAL RESPONSE AFTER NEOADJUVANT CHEMORADIATION THERAPY: A SINGLE-CENTER EXPERIENCE.
Kokaine L; Radzina M; Liepa M; Gerina-Berzina A; Sīviņa E; Nikolajeva J; Gardovskis A; Gardovskis J; Miklaševičs E
Exp Oncol; 2024 May; 46(1):53-60. PubMed ID: 38852052
[TBL] [Abstract][Full Text] [Related]
2. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
[No Abstract] [Full Text] [Related]
3. ["Watch and wait" strategy after neoadjuvant therapy for rectal cancer: status survey of perceptions, attitudes and treatment selection in Chinese surgeons].
Sun TT; Wang L; Yao YF; Peng YF; Zhao J; Zhan TC; Leng JH; Wang HY; Chen N; Chen PJ; Li YJ; Zhang X; Liu XZ; Zhang Y; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jun; 22(6):550-559. PubMed ID: 31238634
[No Abstract] [Full Text] [Related]
4. [Outcome of watch and wait strategy or organ preservation for rectal cancer following neoadjuvant chemoradiotherapy: report of 35 cases from a single cancer center].
Wu A; Wang L; Du C; Peng Y; Yao Y; Zhao J; Zhan T; Cai Y; Li Y; Sun Y; Ji J
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Apr; 20(4):417-424. PubMed ID: 28440523
[TBL] [Abstract][Full Text] [Related]
5. [Application value of colonoscopic assessment in "watch and wait" strategy for mid-lower rectal cancer after neoadjuvant chemoradiotherapy].
Li SJ; Wang L; Zhang XY; Li YH; Li ZW; Wu Q; Sun YS; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jul; 22(7):648-655. PubMed ID: 31302963
[No Abstract] [Full Text] [Related]
6. [Long-term outcome of patients with rectal cancer who achieve complete or near complete clinical responses after neoadjuvant therapy: a multicenter registry study of data from the Chinese Watch and Wait Database].
Zhao YM; Wang WH; Zhang W; Wang L; Li S; Wang JW; Liao LE; Yu GY; Sun Z; Qu YL; Gong Y; Lu Y; Wu T; Li YF; Wang Q; Zhao GH; Xiao Y; Ding PR; Zhang Z; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Apr; 27(4):372-382. PubMed ID: 38644243
[No Abstract] [Full Text] [Related]
7. [Comparison of long-term efficacy between watch and wait strategy and total mesorectal excision in locally advanced rectal cancer patients with clinical complete response after neoadjuvant therapy].
Wang XH; Zhou CJ; Zhang S; Wang QX; Xiao WW; Ding PR; Chen G; Pan ZZ; Zeng ZF; Gao YH
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):266-273. PubMed ID: 32192306
[No Abstract] [Full Text] [Related]
8. [Long-term prognostic analysis on complete/near-complete clinical remission for mid-low rectal cancer after neoadjuvant chemoradiotherapy].
Wang L; Li S; Zhang X; Sun T; Du C; Chen N; Peng Y; Yao Y; Zhan T; Zhao J; Cai Y; Li Y; Wang W; Li Z; Sun Y; Ji J; Wu A
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Nov; 21(11):1240-1248. PubMed ID: 30506534
[TBL] [Abstract][Full Text] [Related]
9. Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry study.
Fernandez LM; São Julião GP; Figueiredo NL; Beets GL; van der Valk MJM; Bahadoer RR; Hilling DE; Meershoek-Klein Kranenbarg E; Roodvoets AGH; Renehan AG; van de Velde CJH; Habr-Gama A; Perez RO;
Lancet Oncol; 2021 Jan; 22(1):43-50. PubMed ID: 33316218
[TBL] [Abstract][Full Text] [Related]
10. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
[No Abstract] [Full Text] [Related]
11. Outcomes of Patients With Local Regrowth After Nonoperative Management of Rectal Cancer After Neoadjuvant Chemoradiotherapy.
Cotti GC; Pandini RV; Braghiroli OFM; Nahas CSR; Bustamante-Lopez LA; Marques CFS; Imperiale AR; Ribeiro U; Salvajoli B; Hoff PM; Nahas SC
Dis Colon Rectum; 2022 Mar; 65(3):333-339. PubMed ID: 34775415
[TBL] [Abstract][Full Text] [Related]
12. Low rectal cancer treatment strategies: a cohort study assessing watch and wait.
Pinto JC; Pereira AD; Pimenta A; Pedro C; Fernandez G; Marques I; Miguel I; Freire J; Maciel J; Venâncio J; D'Orey L; Mirones L; Limbert M; Labareda M; Chaves P; Fonseca R; Barroca R; Ferreira T; Marques T; Rosa I
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2631-2638. PubMed ID: 32435893
[TBL] [Abstract][Full Text] [Related]
13. The watch-and-wait strategy versus surgical resection for rectal cancer patients with a clinical complete response after neoadjuvant chemoradiotherapy.
Wang QX; Zhang R; Xiao WW; Zhang S; Wei MB; Li YH; Chang H; Xie WH; Li LR; Ding PR; Chen G; Zeng ZF; Wang WH; Wan XB; Gao YH
Radiat Oncol; 2021 Jan; 16(1):16. PubMed ID: 33468176
[TBL] [Abstract][Full Text] [Related]
14. Organ Preservation in Patients with Rectal Cancer Treated with Total Neoadjuvant Therapy.
Jimenez-Rodriguez RM; Quezada-Diaz F; Hameed I; Kalabin A; Patil S; Smith JJ; Garcia-Aguilar J
Dis Colon Rectum; 2021 Dec; 64(12):1463-1470. PubMed ID: 34508014
[TBL] [Abstract][Full Text] [Related]
15. Intentional Watch and Wait or Organ Preservation Surgery Following Neoadjuvant Chemoradiotherapy Plus Consolidation CAPEOX for MRI-defined Low-risk Rectal Cancer: Findings From a Prospective Phase 2 Trial (PKUCH-R01 Trial, NCT02860234).
Wang L; Zhang XY; Zhao YM; Li SJ; Li ZW; Sun YS; Wang WH; Wu AW;
Ann Surg; 2023 Apr; 277(4):647-654. PubMed ID: 35766394
[TBL] [Abstract][Full Text] [Related]
16. Is neoadjuvant chemoradiation with dose-escalation and consolidation chemotherapy sufficient to increase surgery-free and distant metastases-free survival in baseline cT3 rectal cancer?
São Julião GP; Habr-Gama A; Vailati BB; Aguilar PB; Sabbaga J; Araújo SEA; Mattacheo A; Alexandre FA; Fernandez LM; Gomes DB; Gama-Rodrigues J; Perez RO
Eur J Surg Oncol; 2018 Jan; 44(1):93-99. PubMed ID: 29217398
[TBL] [Abstract][Full Text] [Related]
17. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
[No Abstract] [Full Text] [Related]
18. Long-term outcomes of real world 'watch and wait' data for rectal cancer after neoadjuvant chemoradiotherapy.
Simpson G; Hopley P; Wilson J; Day N; Haworth A; Montazeri A; Smith D; Titu L; Anderson J; Agbamu D; Walsh C
Colorectal Dis; 2020 Nov; 22(11):1568-1576. PubMed ID: 32686268
[TBL] [Abstract][Full Text] [Related]
19. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis.
Dossa F; Chesney TR; Acuna SA; Baxter NN
Lancet Gastroenterol Hepatol; 2017 Jul; 2(7):501-513. PubMed ID: 28479372
[TBL] [Abstract][Full Text] [Related]
20. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis.
Renehan AG; Malcomson L; Emsley R; Gollins S; Maw A; Myint AS; Rooney PS; Susnerwala S; Blower A; Saunders MP; Wilson MS; Scott N; O'Dwyer ST
Lancet Oncol; 2016 Feb; 17(2):174-183. PubMed ID: 26705854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
